BIOMAT Database Logo BIOMAT Database Logo

The polychemotherapeutic treatment of advanced breast cancer. 1977

I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward

UI MeSH Term Description Entries
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
Polychemotherapeutic treatment of patients with metastatic breast cancer.
January 1986, Acta medica Hungarica,
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
[Advanced carcinoma of the breast. Results of a polychemotherapeutic protocol].
September 1982, Minerva ginecologica,
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
[Polychemotherapeutic treatment of pulmonary neoplasms].
June 1970, Giornale di pneumologia,
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
The treatment of advanced breast cancer.
October 1962, The American journal of nursing,
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
The treatment of advanced breast cancer.
October 1969, The Medical journal of Australia,
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
[Treatment of advanced breast cancer].
January 1968, Cirugia y cirujanos,
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
Treatment of advanced breast cancer.
February 1969, British medical journal,
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
Treatment of advanced breast cancer.
March 1983, British medical journal (Clinical research ed.),
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
Treatment of advanced breast cancer.
December 1981, The New England journal of medicine,
I Brown, and K Arthur, and A J Banks, and W H Bond, and M S Chowdhury, and W E Freeman, and G M Holme, and W G Jones, and G A Newsholme, and H W Ward
[Mono-polychemotherapeutic treatment? The opportunities and limits].
January 1999, Minerva medica,
Copied contents to your clipboard!